Samuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,000 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $24.92, for a total transaction of $299,040.00. Following the completion of the transaction, the chief executive officer now owns 1,063,525 shares of the company’s stock, valued at $26,503,043. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, June 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.66, for a total transaction of $259,920.00.
• On Tuesday, May 28th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $23.18, for a total transaction of $278,160.00.

Enliven Therapeutics Trading Down 2.7 %

ELVN stock traded down $0.75 during mid-day trading on Monday, reaching $26.56. 244,936 shares of the stock traded hands, compared to its average volume of 271,236. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $27.67. The stock’s fifty day moving average is $22.62 and its 200-day moving average is $19.20. The company has a market cap of $1.25 billion, a P/E ratio of -13.76 and a beta of 1.11.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. Equities research analysts expect that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC grew its holdings in Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares during the last quarter. Baker BROS. Advisors LP acquired a new position in Enliven Therapeutics during the first quarter valued at approximately $2,020,000. Bank of New York Mellon Corp grew its stake in shares of Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares during the last quarter. Blackstone Inc. bought a new position in Enliven Therapeutics during the first quarter worth $443,000. Finally, SG Americas Securities LLC raised its stake in Enliven Therapeutics by 17.8% during the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after purchasing an additional 2,041 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ELVN shares. Robert W. Baird started coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective for the company. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.